U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H13ClFN3.C4H4O4
Molecular Weight 441.839
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of MIDAZOLAM MALEATE

SMILES

OC(=O)\C=C/C(O)=O.CC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12

InChI

InChIKey=XYGVIBXOJOOCFR-BTJKTKAUSA-N
InChI=1S/C18H13ClFN3.C4H4O4/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13;5-3(6)1-2-4(7)8/h2-9H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C18H13ClFN3
Molecular Weight 325.767
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Midazolam, previously marketed under the trade name Versed, is a medication used for anesthesia, procedural sedation, trouble sleeping, and severe agitation. Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the γ-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil. Data from published reports of studies in pediatric patients clearly demonstrate that oral midazolam provides safe and effective sedation and anxiolysis prior to surgical procedures that require anesthesia as well as before other procedures that require sedation but may not require anesthesia. The most commonly reported effective doses range from 0.25 to 1 mg/kg in children (6 months to <16 years). The single most commonly reported effective dose is 0.5 mg/kg. Time to onset of effect is most frequently reported as 10 to 20 minutes. The effects of midazolam on the CNS are dependent on the dose administered, the route of administration, and the presence or absence of other medications.

CNS Activity

Curator's Comment: Midazolam is a benzodiazepine. It works in the central nervous system (brain) to cause sleepiness, muscle relaxation, and short-term memory loss, and to reduce anxiety.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Midazolam

Approved Use

Midazolam hydrochloride syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. Midazolam hydrochloride syrup is intended for use in monitored settings only and not for chronic or home use (see WARNINGS). MIDAZOLAM HYDROCHLORIDE SYRUP MUST BE USED AS SPECIFIED IN THE LABEL. Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours

Launch Date

5.03884808E11
Primary
Midazolam

Approved Use

Midazolam HCl syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia. Midazolam HCl syrup is intended for use in monitored settings only and not for chronic or home use (see WARNINGS). MIDAZOLAM HCl SYRUP MUST BE USED AS SPECIFIED IN THE LABEL. Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours

Launch Date

5.03884808E11
Primary
Midafresa

Approved Use

Epilepsy

Launch Date

1.41877445E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
54.7 ng/mL
5 mg single, nasal
dose: 5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
113.9 ng/mL
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
35.124 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: oral
experiment type: single
co-administered:
MIDAZOLAM plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
126.2 ng × h/mL
5 mg single, nasal
dose: 5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
402.7 ng × h/mL
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
100.935 ng*h/mL
6 mg single, oral
dose: 6 mg
route of administration: oral
experiment type: single
co-administered:
MIDAZOLAM plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
103.348 ng*h/mL
6 mg single, oral
dose: 6 mg
route of administration: oral
experiment type: single
co-administered:
MIDAZOLAM plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
30 nM*h
2 mg single, oral
dose: 2 mg
route of administration: oral
experiment type: single
co-administered:
MIDAZOLAM plasma
Homo sapiens
population: healthy
age: adults
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
5 mg single, nasal
dose: 5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3%
10 mg single, intramuscular
dose: 10 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
MIDAZOLAM unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 mg single, intranasal
MTD
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Co-administed with::
sufentanil(0.4 mg/kg)
Sources:
unknown, 18 - 65 years
n = 30
Health Status: unknown
Condition: gastroscopy
Age Group: 18 - 65 years
Sex: unknown
Population Size: 30
Sources:
Other AEs: Nausea, Hypotension...
Other AEs:
Nausea
Hypotension
Sources:
5 mg 1 times / month multiple, intranasal (mean)
Recommended
Dose: 5 mg, 1 times / month
Route: intranasal
Route: multiple
Dose: 5 mg, 1 times / month
Sources:
unhealthy, > 12 years
n = 161
Health Status: unhealthy
Condition: seizure clusters
Age Group: > 12 years
Sex: unknown
Population Size: 161
Sources:
Disc. AE: Nasal discomfort, Somnolence...
Other AEs: Nasal discomfort, Somnolence...
AEs leading to
discontinuation/dose reduction:
Nasal discomfort (1 patient)
Somnolence (1 patient)
Other AEs:
Nasal discomfort (12.4%)
Somnolence (9.3%)
Sources:
5 mg single, intranasal (mean)
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unknown, adult and children
n = 87740
Health Status: unknown
Condition: gastroscopy
Age Group: adult and children
Sex: M+F
Population Size: 87740
Sources:
Other AEs: Hypoxemia, Hypotension...
Other AEs:
Hypoxemia (90 patients)
Hypotension (5 patients)
Sources:
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Other AEs: Somnolence, Headache...
Other AEs:
Somnolence (10%)
Headache (7%)
Dysarthria (2%)
Nasal discomfort (5%)
Throat irritation (2%)
Rhinorrhea (3%)
Lacrimation increased (1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypotension
5 mg single, intranasal
MTD
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Co-administed with::
sufentanil(0.4 mg/kg)
Sources:
unknown, 18 - 65 years
n = 30
Health Status: unknown
Condition: gastroscopy
Age Group: 18 - 65 years
Sex: unknown
Population Size: 30
Sources:
Nausea
5 mg single, intranasal
MTD
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Co-administed with::
sufentanil(0.4 mg/kg)
Sources:
unknown, 18 - 65 years
n = 30
Health Status: unknown
Condition: gastroscopy
Age Group: 18 - 65 years
Sex: unknown
Population Size: 30
Sources:
Nasal discomfort 1 patient
Disc. AE
5 mg 1 times / month multiple, intranasal (mean)
Recommended
Dose: 5 mg, 1 times / month
Route: intranasal
Route: multiple
Dose: 5 mg, 1 times / month
Sources:
unhealthy, > 12 years
n = 161
Health Status: unhealthy
Condition: seizure clusters
Age Group: > 12 years
Sex: unknown
Population Size: 161
Sources:
Somnolence 1 patient
Disc. AE
5 mg 1 times / month multiple, intranasal (mean)
Recommended
Dose: 5 mg, 1 times / month
Route: intranasal
Route: multiple
Dose: 5 mg, 1 times / month
Sources:
unhealthy, > 12 years
n = 161
Health Status: unhealthy
Condition: seizure clusters
Age Group: > 12 years
Sex: unknown
Population Size: 161
Sources:
Nasal discomfort 12.4%
5 mg 1 times / month multiple, intranasal (mean)
Recommended
Dose: 5 mg, 1 times / month
Route: intranasal
Route: multiple
Dose: 5 mg, 1 times / month
Sources:
unhealthy, > 12 years
n = 161
Health Status: unhealthy
Condition: seizure clusters
Age Group: > 12 years
Sex: unknown
Population Size: 161
Sources:
Somnolence 9.3%
5 mg 1 times / month multiple, intranasal (mean)
Recommended
Dose: 5 mg, 1 times / month
Route: intranasal
Route: multiple
Dose: 5 mg, 1 times / month
Sources:
unhealthy, > 12 years
n = 161
Health Status: unhealthy
Condition: seizure clusters
Age Group: > 12 years
Sex: unknown
Population Size: 161
Sources:
Hypotension 5 patients
5 mg single, intranasal (mean)
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unknown, adult and children
n = 87740
Health Status: unknown
Condition: gastroscopy
Age Group: adult and children
Sex: M+F
Population Size: 87740
Sources:
Hypoxemia 90 patients
5 mg single, intranasal (mean)
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unknown, adult and children
n = 87740
Health Status: unknown
Condition: gastroscopy
Age Group: adult and children
Sex: M+F
Population Size: 87740
Sources:
Lacrimation increased 1%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Somnolence 10%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Dysarthria 2%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Throat irritation 2%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Rhinorrhea 3%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Nasal discomfort 5%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Headache 7%
5 mg single, intranasal
Recommended
Dose: 5 mg
Route: intranasal
Route: single
Dose: 5 mg
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: intermittent, stereotypic episodes of frequent seizure activity
Age Group: adult
Sex: unknown
Population Size: 91
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 3.7 uM]
yes [Ki 5.8 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: INHIBITORS: Coadministration with cimetidine: AUC increase of MDZ=10-102%; diltiazem: AUC increase of MDZ=275%; erythromycin: AUC increase of MDZ=281-341; fluconazole: AUC increase of MDZ=250%; grapefruit juice: AUC increase of 52%; itraconazole: AUC increase of MDZ=240-980%; ketoconazole: AUC increase of MDZ=1490%; ranitidine: AUC increase of MDZ=9-66%. INDUCERS: coadministration with carbamazepine: AUC decrease of MDZ=94%; phenytoin: AUC decrease of MDZ=94%; rifampin: AUC decrease of MDZ=96%;
Page: 11,12
minor
minor
minor
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Propofol vs midazolam for ICU sedation : a Canadian multicenter randomized trial.
2001 Apr
Stress response in infants undergoing cardiac surgery: a randomized study of fentanyl bolus, fentanyl infusion, and fentanyl-midazolam infusion.
2001 Apr
Distinct functional and pharmacological properties of tonic and quantal inhibitory postsynaptic currents mediated by gamma-aminobutyric acid(A) receptors in hippocampal neurons.
2001 Apr
Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites.
2001 Apr
Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
2001 Apr
Preparation, premedication, and surveillance.
2001 Feb
[Epileptogenic drugs in anesthesia].
2001 Feb
Propofol as a continuous infusion during cardiopulmonary bypass does not affect changes in serum free fatty acids.
2001 Feb
Small doses of remifentanil or sufentanil for blunting cardiovascular changes induced by tracheal intubation: a double-blind comparison.
2001 Feb
Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo.
2001 Feb
[Fastrach laryngeal mask, sevoflurane and remifentanil: an anesthetic alternative for the myasthenic patient].
2001 Feb
Pharmacoeconomic assessment of propofol 2% used for prolonged sedation.
2001 Feb
Oral transmucosal midazolam premedication for preschool children.
2001 Feb
Cardiovascular effects of sevoflurane, isoflurane, halothane, and fentanyl-midazolam in children with congenital heart disease: an echocardiographic study of myocardial contractility and hemodynamics.
2001 Feb
Effect of midazolam pretreatment on induction dose requirements of propofol in combination with fentanyl in younger and older adults.
2001 Feb
Monitoring of end-tidal carbon dioxide partial pressure changes during infrarenal aortic cross-clamping: a non-invasive method to predict unclamping hypotension.
2001 Feb
Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
2001 Feb
Propofol depressed neutrophil hydrogen peroxide production more than midazolam, whereas adhesion molecule expression was minimally affected by both anesthetics in rats with abdominal sepsis.
2001 Feb
The use of esmolol as an alternative to remifentanil during desflurane anesthesia for fast-track outpatient gynecologic laparoscopic surgery.
2001 Feb
In situ nasal absorption of midazolam in rats.
2001 Feb 1
[Premedication for endoscopy].
2001 Feb 2
Sedation for children requiring wound repair: a randomised controlled double blind comparison of oral midazolam and oral ketamine.
2001 Jan
Intra-nasal midazolam in conscious sedation of young paediatric dental patients.
2001 Jan
Pulse oximetry saturation levels during routine unsedated diagnostic upper gastrointestinal endoscopy.
2001 Jan
[Anesthetic experience of emergency coronary artery bypass graft operation in a patient with cardioamyloidosis].
2001 Jan
[Anesthetic management for mitral valve replacement in a patient with idiopathic hypereosinophilic syndrome].
2001 Jan
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.
2001 Jan
Propofol versus midazolam regarding their antioxidant activities.
2001 Jan
Influence of patient posture on oxygen saturation during fibre-optic bronchoscopy.
2001 Jan
The immunomodulatory effects of prolonged intravenous infusion of propofol versus midazolam in critically ill surgical patients.
2001 Jan
Digitally assisted acromioplasty: the effect of interscalene block on this new surgical technique.
2001 Jan
Intranasal midazolam for treating febrile seizures in children. Safety is as important as efficacy.
2001 Jan 13
Intranasal midazolam for treating febrile seizures in children. Caution is required in applying hospital based evidence to primary care population.
2001 Jan 13
Intranasal midazolam for treating febrile seizures in children. Buccal midazolam should be preferred to nasal midazolam.
2001 Jan 13
Intranasal midazolam for treating febrile seizures in children. Caution is advised in interpreting trial conclusions.
2001 Jan 13
Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray.
2001 Jan 5
The anxiolytic effects of intra-hippocampal midazolam are antagonized by intra-septal L-glutamate.
2001 Jan 5
Synergistic analgesic effects of intrathecal midazolam and NMDA or AMPA receptor antagonists in rats.
2001 Mar
Selective spinal anesthesia for outpatient laparoscopy. II: epinephrine and spinal cord function.
2001 Mar
Drugs and syringe drivers: a survey of adult specialist palliative care practice in the United Kingdom and Eire.
2001 Mar
Midazolam reduces the dose of propofol required for induction of anaesthesia and laryngeal mask airway insertion.
2001 Mar
Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
2001 Mar
Comparison of midazolam with or without fentanyl for conscious sedation and hemodynamics in coronary angiography.
2001 Mar
The effect of anxiety and personality on the pharmacokinetics of oral midazolam.
2001 Mar
Evaluation of the safety and efficacy of repeated sedations for the radiotherapy of young children with cancer: a prospective study of 1033 consecutive sedations.
2001 Mar 1
Management of background pain and anxiety in critically burned children requiring protracted mechanical ventilation.
2001 Mar-Apr
Burn patients' pain and anxiety experiences.
2001 Mar-Apr
Onset and duration of action of rocuronium--from tracheal intubation, through intense block to complete recovery.
2001 May
Characterization of discriminative stimulus effects of the neuroactive steroid pregnanolone.
2001 May
Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates.
2001 May
Patents

Sample Use Guides

Midazolam hydrochloride syrup is indicated for use as a single dose (0.25 to 1 mg/kg with a maximum dose of 20 mg) for preprocedural sedation and anxiolysis in pediatric patients. Midazolam hydrochloride syrup is not intended for chronic administration.
Route of Administration: Oral
In Vitro Use Guide
Midazolam (1 uM) decreased GABA-activated currents in acutely dissociated neurons, isolated from the medial septum/nucleus of the diagonal band (MS/nDB) of the adult rat brains.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:23:37 UTC 2023
Edited
by admin
on Fri Dec 15 15:23:37 UTC 2023
Record UNII
77520S18SE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIDAZOLAM MALEATE
MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
MIDAZOLAM MALEATE [MART.]
Common Name English
NSC-313452
Code English
4H-IMIDAZO(1,5-A)(1,4)BENZODIAZEPINE, 8-CHLORO-6-(2-FLUOROPHENYL)-1-METHYL-, (Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
MIDAZOLAM (AS MALEATE)
Common Name English
MIDAZOLAM MALEATE [USAN]
Common Name English
RO 21-3981/001
Code English
RO-213981-003
Code English
Midazolam maleate [WHO-DD]
Common Name English
MIDAZOLAM MALEATE [MI]
Common Name English
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine maleate (1:1)
Common Name English
RO-21-3981/001
Code English
Code System Code Type Description
RXCUI
142441
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY RxNorm
DRUG BANK
DBSALT002303
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY
CAS
59467-94-6
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY
ChEMBL
CHEMBL655
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY
SMS_ID
100000076068
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY
NSC
313452
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY
EVMPD
SUB14573MIG
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY
NCI_THESAURUS
C167002
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY
ECHA (EC/EINECS)
261-775-0
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY
MERCK INDEX
m7531
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY Merck Index
FDA UNII
77520S18SE
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY
PUBCHEM
5384200
Created by admin on Fri Dec 15 15:23:37 UTC 2023 , Edited by admin on Fri Dec 15 15:23:37 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY